Buckeyes/narmac - Though DM is President & CEO he is one vote on the Board. If the larger shareholders decide that they would like to accept a deal from a BP that is shy of what DM believes is the correct number then they will exercise their  influence. Two shareholders can decide any vote. Both of those shareholders are very good business people. I don't forsee any issues that would negatively affect retailers as there is a good balance between management and ownership.

Did anyone happen to look and see what the potential sales or actual sales of the drugs that fail their Top Line and then went on to be bought out that ssp mentioned in his post this morning? I didn't but wondered how many of those drugs had Mega Blockbuster potential or in excess of $5 billion in annual sales? The tickers were ACHN, ECYT, MDVN, and PCYC. Most of the drugs being developed have potential annual sales of less than $5 billion.

There are very few drugs that have the potential sales that ABL has IF it is able to get approval to be sold, IF the full data may warrant it. What is really unique about ABL is that there is potentially 3 separate indications that have Mega Blockbuster potential. If there are some spectacular results in some areas then maybe the larger shareholders will sway the direction we end up taking. 

tada